FAP and neoplasm: To address challenges inherent in co-administering IL-15 with CAR-T cells targeting the tumor microenvironment, we developed a novel CAR construct that incorporates intrinsic IL-15 secretion capacity directly into FAP-targeted CAR-T cells.